Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various first- and second-line and rescue therapies and (ii) the associated reinfection rates in patients.

Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis

Hassan, Cesare;
2009-01-01

Abstract

Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various first- and second-line and rescue therapies and (ii) the associated reinfection rates in patients.
2009
Helicobacter pylori
Drug Therapy
Combination
Helicobacter Infections
Humans
Lymphoma
B-Cell
Marginal Zone
Recurrence
Statistics as Topic
Stomach Neoplasms
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/75607
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 85
  • ???jsp.display-item.citation.isi??? 67
social impact